Introduction
============

Productive HIV assembly requires the coordinated mobilization of both viral and cellular host factors toward the plasma membrane (PM) domains where formation of viral particles takes place. This process is orchestrated by the viral precursor protein Pr55^Gag^, a myristoylated polyprotein that contains four major structural domains: matrix, capsid, nucleocapsid, and p6. A highly basic region present in the matrix domain is responsible for binding to phosphatidylinositol 4,5-bisphosphate (PI(4,5)P~2~), a phosphoinositide present at the inner leaflet of the PM. Upon binding PI(4,5)P~2~, Pr55^Gag^ molecules multimerize and form a spherical shell that packages the genomic RNA into the nascent virion. Concomitantly, the viral envelope protein Env is recruited and incorporated into the nascent viral particles. During virus release, the viral protease cleaves Pr55^Gag^ into its constituent proteins, giving rise to mature infectious viral particles ([@bib1]; [@bib61]). Whereas in CD4^+^ T cells, HIV-1 assembles at discrete domains of the PM, in macrophages, HIV-1 budding takes place in specialized, intracellular sequestered portions of the PM known as virus-containing compartments (VCCs; [@bib16]; [@bib31]; [@bib71]; [@bib4]; [@bib3]). In both cases, the HIV-1 assembly domains present a peculiar enrichment for a variety of tetraspanins, such as CD9, CD63, CD81, and CD82 ([@bib7]; [@bib16]; [@bib29]). However, the role played by tetraspanins at the site of HIV-1 assembly still remains an open question in the field.

The trafficking of late endosomes/secretory lysosome toward the site of HIV-1 assembly has been shown to be required for the dissemination of HIV-1 infection in CD4^+^ T cells ([@bib29]). Indeed, cells isolated from Chediak--Higashi and Hermansky--Pudlack syndrome patients, two rare autosomal recessive diseases that affect late endosomes/lysosomes, are deficient in HIV-1 production ([@bib19]; [@bib28]). Moreover, several cellular proteins implicated in endosomal function have been shown to be required for Pr55^Gag^ trafficking ([@bib1]). Along these lines, it has been proposed that during viral assembly and release, HIV-1 hijacks the cellular exosome secretion pathway ([@bib21]; [@bib7]). Exosome secretion takes place after the fusion of the limiting membrane of multivesicular endosomes (MVEs) with the PM, resulting in the extracellular release of their intraluminal vesicles, which are then named as exosomes ([@bib62]). We previously showed that small GTPases Rab27a and Rab27b control exosome secretion by promoting the docking of MVEs to the PM ([@bib50]). Taking into consideration the role played by Rab27a in regulating the trafficking of late endosomes and exosome secretion and the proposed link between these processes and HIV-1 assembly, in this study, we undertook the analysis of the role played by late endosomal compartments in HIV-1 budding by using cells deficient in Rab27a.

We show that Rab27a controls the recruitment of PI4KIIα (phosphatidylinositol 4-kinase type 2 α) from endosomes to the PM, promoting high levels of phosphatidylinositol 4-phosphate (PI(4)P) and fueling PI(4,5)P~2~ production. This, in turn, favors the recruitment of Pr55^Gag^ and HIV-1 assembly. We also show that Rab27a uses its effector Slp2a to promote PI4KIIα recruitment and the production of PI(4)P and PI(4,5)P2 at the PM. In summary, our study identifies a Rab27a-controlled endosomal trafficking pathway usurped by HIV-1 during viral assembly.

Results
=======

Silencing of Rab27a inhibits HIV-1 replication in CD4^+^ T cells and macrophages
--------------------------------------------------------------------------------

The role of Rab27a in HIV-1 replication was first analyzed by silencing the expression of this small GTPase in the CD4^+^ T cell line Jurkat by using two different Rab27a shRNA sequences ([Fig. 1 A](#fig1){ref-type="fig"}). Upon infection with a VSV-G--pseudotyped HIV-1 strain, which circumvents the viral receptors and enters the cells through endocytosis ([@bib48]), the two Rab27a shRNA sequences significantly impaired HIV-1 replication, as determined by reduced production of p24 antigen at day 5 postinfection (p.i.; [Fig. 1 B](#fig1){ref-type="fig"}). Given that the strongest effect on Rab27a mRNA silencing was observed with shRNA sequence \#2, this construct was chosen for the next set of experiments. The ability of shRNA\#2 to silence Rab27a expression was confirmed by immunoblotting ([Fig. 1 C](#fig1){ref-type="fig"}). The percentage of live cells in control and Rab27a-silenced cells, evaluated by Annexin V/propidium iodide staining, showed that Rab27a silencing did not affect cell viability ([Fig. 1 D](#fig1){ref-type="fig"}). To rule out off-target effects of the shRNA treatment, we rescued Rab27a expression in Rab27a-silenced cells and observed a reversion of the inhibition in HIV-1 replication ([Fig. S1, A and B](http://www.jcb.org/cgi/content/full/jcb.201409082/DC1){#supp1}), confirming the specificity of the results.

![**Rab27a is required for HIV replication in CD4^+^ T lymphocytes and macrophages.** (A--D) Jurkat cells were transduced with lentivirus encoding different Rab27a shRNA sequences (A and B; open bars), or a control scrambled shRNA (black bars). (A) Rab27a mRNA levels were determined by qPCR. Means ± SD of a representative experiment (*n* = 3) performed in triplicates is shown. (B) Cells (3 × 10^4^/0.1 ml) were infected with a VSV-G--pseudotyped HIV (20 ng p24/ml), and p24 production was evaluated in cell supernatants at day 5 p.i. Means ± SD of two independent experiments expressed as percentages of p24 production of control cells are shown. (C) Immunoblot of Rab27a protein levels. Actin was used as a loading control. (D) Cell viability was determined at day 7 after puromycin selection by annexin V staining and propidium iodide exclusion followed by FACS analysis. Dot plots from a representative experiment (*n* = 4) are shown. Percentage of death cells (annexin V^+^/propidium iodide^+^) is indicated. (E--G) Control (closed circles) and Rab27a-silenced Jurkat cells (open circles; 3 × 10^4^/0.1 ml) were infected with HIV (IIIb strain; 50 ng p24/ml). The production of p24 (E) and the percentages of p24-positive cells (F and G) were determined by ELISA and FACS analysis, respectively. Representative dot plots (F) and the percentages of infected cells (G) from a representative experiment (*n* = 6) are shown. (H) Virus release assay. Cells were spinoculated with a high MOI of VSV-G--pseudotyped HIV strain. 48 h later, the amounts of cell-associated and released virus were analyzed by immunoblotting. (I and J) Control and Rab27a-silenced PBMCs (I) or PBMCs from a GS patient and an age-matched control (J) were infected with a VSV-G--pseudotyped HIV-1 (200 and 50 ng/ml p24, respectively). The production of p24 was evaluated at different days p.i. Results from a representative experiment (*n* = 3 and *n* = 2) performed in triplicates are expressed as the means ± SD. (K) Quantification of p24 antigen in cell supernatants from control (closed triangles) or Rab27a-silenced (open triangles) MDMs (5 × 10^4^/0.1 ml) infected with HIV-1(BaL strain; 50 ng p24/ml). Kinetics of p24 production from a representative experiment are shown in the left graph. p24 production by cells from seven different blood donors at day 5 p.i. is shown in the right graph. Asterisks indicate statistically significant differences from the control: \*\*, P \< 0.01. KD, knockdown.](JCB_201409082_Fig1){#fig1}

The kinetics of HIV-1 production was then evaluated by infecting Jurkat cells with a CXCR4-tropic HIV-1 strain (IIIb) at a low MOI. In these experimental conditions, HIV-1 replication in Rab27a-silenced cells was also severely impaired ([Fig. 1, E, F, and G](#fig1){ref-type="fig"}).

Further experiments were performed to assess whether Rab27a was required for early or late stages of the viral replication cycle. The lack of differences between control and Rab27a-silenced cells in (a) cell surface levels of CD4 and CXCR4 (HIV-1 receptor and coreceptor, respectively; [Fig. S2 A](http://www.jcb.org/cgi/content/full/jcb.201409082/DC1){#supp2}), (b) the amount of HIV-1 attached to the cell surface (measured after coincubating cells and virus at 4°C for 90 min) and internalized (measured after coincubating cells and virus at 37°C; Fig. S2 B), and (c) the susceptibility to HIV-1 infection in a single-cycle assay (Fig. S2, C and D) allowed us to conclude that Rab27a does not interfere with early steps of the HIV-1 replication cycle. To analyze the role of Rab27a in the late stages of the viral replication cycle, cells were spinoculated with HIV-1 at a high MOI to achieve a high percentage of infected cells at 48 h p.i. The amount of cell-associated Pr55^Gag^ in control and Rab27a-silenced cells was similar, showing that, as in the case of wild-type HIV-1, the entry of VSV-G--pseudotyped viral particles is not affected in Rab27a-silenced cells ([Fig. 1 H](#fig1){ref-type="fig"}, left). However, the amount of virus released into the supernatant was dramatically reduced in Rab27a-silenced cells ([Fig. 1 H](#fig1){ref-type="fig"}, right), suggesting that the inhibition of HIV-1 replication observed in Rab27a-silenced cells is mainly caused by a defect in the assembly or release of viral particles. Taking into consideration that the host restriction factor tetherin inhibits HIV-1 release, we next decided to analyze whether Rab27a expression modified tetherin surface expression. Both in uninfected and in HIV-1--infected cells, tetherin expression in Rab27a-silenced cells was comparable to that of control cells (Fig. S2, E--H). Thus, silencing the expression of Rab27a impairs HIV-1 replication by controlling a tetherin-independent late step of the viral replication cycle.

We then analyzed the role of Rab27a in HIV-1 replication in primary CD4^+^ T cells by using two strategies. First, expression of Rab27a was silenced by transducing peripheral blood mononuclear cells (PBMCs) with Rab27a shRNA\#2 (efficiency of silencing: 52%). In addition, PBMCs from a patient with a mutation in Rab27a, a clinical condition known as Griscelli syndrome (GS; [@bib40]), and an age-matched healthy donor were used. In agreement with results obtained in Jurkat cells, Rab27a-deficient lymphocytes produced significantly less virus, as compared with their respective controls ([Fig. 1, I and J](#fig1){ref-type="fig"}). Finally, the role of Rab27a in HIV-1 production was analyzed in primary macrophages. In this case too, we observed that Rab27a silencing (efficiency of silencing: \>90%) impaired HIV-1 replication ([Fig. 1 K](#fig1){ref-type="fig"}). We conclude that Rab27a is required for a late step of the HIV-1 replication cycle, both in CD4^+^ T cells and monocyte-derived macrophages (MDMs).

Rab27a controls the formation of the HIV-1 assembly platform and Gag recruitment to cell membranes in CD4^+^ T cells and macrophages
------------------------------------------------------------------------------------------------------------------------------------

Rab27 controls the intracellular trafficking of MVEs ([@bib50]) and of several lysosome-related organelles (LROs) in different cell types ([@bib55]). To explore whether the impairment of HIV-1 assembly observed in Rab27a-silenced cells was related to a defect in the trafficking of these organelles, we performed laser-scanning confocal microscopy (LSCM) in live cells using the tetraspanin CD63 and LysoTracker (a dye that labels acidic compartments) as markers of LRO/endosome identity. Rab27a-silenced cells presented a marked increase in the size of GFP-CD63^+^ compartments concomitantly with a reduction in the amount of PM-associated CD63, as compared with control cells ([Fig. 2 A](#fig2){ref-type="fig"}). This phenotype could be reverted by the expression of exogenous Rab27a ([Fig. S3, A and B](http://www.jcb.org/cgi/content/full/jcb.201409082/DC1){#supp3}). The reduction in PM levels of endogenous CD63 was also indicated by FACS analysis ([Fig. 2, B and C](#fig2){ref-type="fig"}). To further analyze whether the reduction in PM levels of CD63 in Rab27a-silenced cells was caused by a defect in the trafficking of CD63^+^ endosomes, we performed a CD4^+^ T cell degranulation assay based on the quantification of CD63 cell surface translocation after stimulation of the cells with PMA-ionomycin. Translocation of CD63 from internal compartments to the PM was severely impaired in Rab27a-silenced cells (Fig. S3, C and D), suggesting that the Rab27a-regulated pathway of endosomal trafficking significantly contributes to PM levels of CD63. To rule out an effect of Rab27a on the functionality of the regular secretory pathway, the secretion of the cytokine granulocyte--macrophage colony-stimulating factor (GM-CSF; that follows the conventional secretory pathway) was assessed by ELISA. No changes in the secretion of this cytokine were observed (Fig. S3 E), confirming previous results showing that Rab27a does not interfere with the regular secretory pathway of the cell ([@bib50]). Altogether, these results suggest that by controlling the trafficking of CD63-positive endosomes/LROs, Rab27a promotes PM localization of CD63 in CD4^+^ T cells.

![**Silencing of Rab27a impairs the recruitment of MVEs to the site of HIV-1 assembly and Pr55^Gag^ association with the PM in Jurkat cells.** (A) LSCM of live control and Rab27a-silenced cells stably expressing CD63-GFP and stained with LysoTracker. (B) FACS plots showing endogenous cell surface CD63 levels in control and Rab27a-silenced cells. Isotype control is shown (gray line). The data shown are from a single representative experiment out of six repeats. For the experiment shown, 10,000 cells from each condition were analyzed. (C) Mean fluorescence intensity (MFI) of cell surface CD63 staining in control and Rab27a-silenced cells (*n* = 6). (D) Immunofluorescence LSCM images of endogenous CD63 and Gag in control and Rab27a-silenced infected Jurkat cells at day 12 p.i. To better visualize Gag cytosolic distribution in Rab27a-silenced cells, the laser power was increased for the acquisition of the green channel. (E) Quantitation of PM versus cytosolic distribution of Gag and of CD63 forming a PM cap versus its intracellular location in 100 cells of each condition. Data are expressed as percentages of cells in each category. (F) LSCM of control and Rab27a-silenced Jurkat cells. Cell surface CD81 was stained in nonpermeabilized cells, and, subsequently, intracellular Gag was stained. (G) Quantitation of PM versus cytosolic distribution of Gag was evaluated in 100 cells of each condition. Data are expressed as percentages of cells in each category. (H) Immunoblots of cell fractions to analyze the distribution of Pr55^Gag^ and p24. The purity of the fractions was assessed by detection of the cytosolic protein GAPDH and the membrane-associated protein calnexin. M, membrane fraction; C, cytosolic fraction. One representative experiment out of three is shown. (I) Ratio of cytosol/membrane distribution of p55, corresponding to three independent experiments. In A, D, and F, transmitted light channel is shown on the right. The quantifications shown in E and G were performed by blinded observers on a per cell basis. KD, knockdown. \*\*, P \< 0.01; \*\*\*, P \< 0.001. Bars, 2 µm.](JCB_201409082_Fig2){#fig2}

We next analyzed the Rab27a-mediated trafficking of CD63^+^ endosomes in HIV-1--infected cells by LSCM immunofluorescence analysis. In agreement with a previous study ([@bib29]), we observed that in HIV-1--infected control cells, CD63 was redistributed from its predominantly internal localization toward a discrete, polarized domain of the PM, where it showed a high level of colocalization with Gag ([Fig. 2 D](#fig2){ref-type="fig"}). In contrast, in Rab27a-silenced cells, CD63^+^ endosomes remained scattered throughout the cytoplasm and the formation of a PM cap of CD63 was not observed. This alteration in endosomal trafficking was concomitant with a change in Gag distribution, which instead of being predominantly associated with the PM, acquired a cytosolic distribution. ([Fig. 2, D and E](#fig2){ref-type="fig"}). These changes were not caused by alterations in the production of Pr55^Gag^, as revealed by analysis of the mean fluorescence intensity of Pr55^Gag^ staining by FACS (mean fluorescence intensity of control cells = 5,848 ± 215 vs. 5,695 ± 197 in Rab27a-silenced cells).

In addition to containing high levels of CD63, the site of HIV-1 assembly also presents an important enrichment in CD81 ([@bib28]; [@bib35]), another tetraspanin that, unlike CD63, is exclusively present at the PM of Jurkat cells and not in endosomes ([Fig. S4 A](http://www.jcb.org/cgi/content/full/jcb.201409082/DC1){#supp4}). LSCM visualization of control cells revealed high levels of colocalization between Pr55^Gag^ and cell surface CD81 in patched regions of the PM ([Fig. 2, F and G](#fig2){ref-type="fig"}). In contrast, as mentioned in the previous paragraph, in Rab27a-silenced cells, Gag exhibited a predominantly cytosolic distribution. In addition, despite the fact that CD81 distribution in uninfected Rab27a-silenced CD4^+^ T cells was comparable to that of control cells (Fig. S4 B), the HIV-1--induced coalescence of CD81 into discrete domains at the PM was inhibited in cells deficient for Rab27a ([Fig. 2, F and G](#fig2){ref-type="fig"}). These results suggest that Rab27a is required for the proper targeting of Pr55^Gag^ to the PM and for the reorganization of the tetraspanin-enriched microdomains (TEMs).

The decrease in the association of Pr55^Gag^ with the PM in Rab27a-silenced cells was confirmed by immunoblot analysis of Pr55^Gag^ distribution in cytosolic and membrane fractions ([Fig. 2, H and I](#fig2){ref-type="fig"}). Interestingly, the p24 capsid protein was detected in association with cell membranes in control cells (likely representing mature viral particles in the process of budding) but not in Rab27a-silenced cells ([Fig. 2 H](#fig2){ref-type="fig"}, longer exposure).

We then decided to analyze Pr55^Gag^ distribution in Rab27a-deficient primary cells. The use of cells from a GS patient recapitulated the phenotype observed in Jurkat cells, further confirming that Rab27a is required for Pr55^Gag^ membrane association ([Fig. 3, A and B](#fig3){ref-type="fig"}). Finally, Pr55^Gag^ distribution was analyzed in MDMs. In agreement with previous studies ([@bib54]; [@bib49]; [@bib16]), we found that in control MDMs, Gag was noticeably concentrated in discrete apparently intracellular compartments, usually identified as VCCs, showing a high degree of colocalization with CD81 ([Fig. 3 C](#fig3){ref-type="fig"}, top). In contrast, in Rab27a-silenced MDMs, Gag exhibited a diffuse, cytosolic staining pattern ([Fig. 3, C](#fig3){ref-type="fig"} \[bottom\] and D).

![**Rab27a controls Pr55^Gag^ recruitment to cell membranes in CD4^+^ T cells and macrophages.** (A) 3D deconvolution fluorescence microscopy of HIV-1--infected PBMCs from a healthy control or a GS patient stained at day 4 p.i. with anti-p24 (green) and anti-CD81 antibodies. Shown is a 3D maximum intensity projection of 10 optical sections acquired at 0.2-µm intervals. (B) Quantitation of PM versus cytosolic distribution of Gag was evaluated by blinded observers on a per-cell basis, in 100 cells of each condition. Data are expressed as percentages of cells in each category. (C) LSCM of HIV-1--infected control or Rab27a-silenced MDMs stained at day 5 p.i. with anti-p24 (green) and anti-CD81 antibodies. (D) Quantification of Gag distribution was performed as described in B. \*\*\*, P \< 0.001. KD, knockdown. Bars, 2 µm.](JCB_201409082_Fig3){#fig3}

Rab27a silencing does not disrupt Env trafficking and processing
----------------------------------------------------------------

Whereas Pr55^Gag^ is recruited from the cytosol directly to the HIV-1 assembly site at the PM, Env reaches the PM through the regular ER--Golgi-dependent secretory pathway ([@bib11]). To rule out an effect of Rab27a in Env trafficking, the expression of total and cell surface Env was determined by FACS analysis in Jurkat cells at day 10 p.i. Consistent with the defect in HIV-1 replication shown in [Fig. 1](#fig1){ref-type="fig"}, the percentage of HIV-infected (Env positive) cells was lower in Rab27a-silenced cells ([Fig. 4, A and B](#fig4){ref-type="fig"}). However, the mean fluorescence intensity of both total and cell surface Env in infected cells was similar in both conditions ([Fig. 4, A and B](#fig4){ref-type="fig"}), indicating that Env expression and trafficking to the PM were not perturbed by Rab27a silencing. Indeed, LSCM analysis showed that in both control and Rab27a-silenced cells, Env exhibited a similar distribution, being present both in intracellular compartments and at the PM ([Fig. 4 C](#fig4){ref-type="fig"}). Moreover, the proteolytic processing of gp160 by furin or furin-like proteases located in the Golgi ([@bib11]), evaluated as the ratio of gp41/gp160, was similar in control and Rab27a-silenced cells ([Fig. 4, D and E](#fig4){ref-type="fig"}), further indicating that Env processing at the Golgi is not altered upon Rab27a silencing. Finally, the infectivity of the viral particles still produced by Rab27a-silenced cells was assessed by infecting the reporter cell line GHOST with equal amounts of HIV-1 secreted by control and Rab27a-silenced cells. The lack of difference in the infectivity of HIV-1 particles produced by control and Rab27a-silenced cells provided functional evidence supporting the notion that Env incorporation into viral particles was not modified upon Rab27a silencing ([Fig. 4 F](#fig4){ref-type="fig"}). Altogether, these results indicate that Rab27a specifically regulates Pr55^Gag^ trafficking without affecting the arrival of Env to the PM.

![**Rab27a silencing does not disrupt Env trafficking.** Control and Rab27a-silenced cells were infected with HIV (IIIb strain) and analyzed at day 10 p.i. (A) Representative FACS plot showing Total (top) and cell surface (bottom) Env levels in uninfected, control, and Rab27a-silenced cells. The percentage of Env-positive cells in the gate containing Env-positive cells is indicated. (B) Quantification of FACS data from three independent experiments. (C) LSCM of control and Rab27a-silenced Jurkat cells stained with anti-p24 (green) and anti-Env antibodies. Differential interference contrast (DIC) images are shown on the right. Bars, 2 µm. (D) gp41 immunoblot on cells spinoculated with a high MOI of vesicular stomatitis virus--pseudotyped HIV at day 3 p.i. (E) gp41/gp160 ratio in control and Rab27a-silenced cells (*n* = 2). (F) Infectivity of the virions produced by control and Rab27a-silenced cells was evaluated using the same amount of p24 (10 ng, as determined by ELISA) to infect GHOST cells (*n* = 3). Results are normalized to the value obtained by infecting GHOST cells with the virus contained in the supernatant of control cells. Error bars show SDs. KD, knockdown; MFI, mean fluorescence intensity. \*\*, P \< 0.01. Bars, 2µm.](JCB_201409082_Fig4){#fig4}

Formation of virological synapses and cell-to-cell transmission of HIV-1 are inhibited in Rab27a-deficient cells
----------------------------------------------------------------------------------------------------------------

Direct cell-to-cell transfer of HIV-1 is a more efficient way of propagating the infection, as compared with transmission by cell-free viral particles ([@bib18]; [@bib10]). Our results anticipate that, by preventing Pr55^Gag^ from reaching the PM, silencing of Rab27a will also limit both the amount of Pr55^Gag^ at the virological synapse and cell--cell transfer of HIV-1. Indeed, silencing of Rab27a expression abrogated the polarized distribution of Gag at zones of cell-to-cell contact in Jurkat cells ([Fig. 5, A and B](#fig5){ref-type="fig"}). A similar phenotype was observed in primary CD4^+^ T cells isolated from a GS patient ([Fig. 5 C](#fig5){ref-type="fig"}) and in MDMs incubated with autologous activated PBMCs ([Fig. 5 D](#fig5){ref-type="fig"}).

![**Formation of the virological synapse and cell-to-cell transmission of HIV are impaired in Rab27a-deficient cells.** (A) Control or Rab27a-silenced Jurkat cells were infected with HIV (IIIB strain). At day 7 p.i., cells were plated onto poly-[l]{.smallcaps}-lysine--coated coverslips and incubated with noninfected target Jurkat cells for 1.5 h. Gag was stained with anti-p24 antibodies and polarization of Gag at the virological synapses was evaluated by LSCM. Representative confocal and DIC images are shown. (B) Quantification of the number of cells showing a polarized distribution of Gag (30 cell conjugates from two independent experiments). (C and D) The ability of primary CD4^+^ T cells from a GS patient and the corresponding healthy control (C) and Rab27a-silenced or control MDMs co-cultured with autologous CD4^+^ T cells to form virological synapses (D) was also evaluated by 3D deconvolution fluorescence microscopy and LSCM, respectively. Representative confocal and DIC images are shown. In C, a 3D maximum intensity projection of 10 optical sections acquired at 0.2-µm intervals is shown. (E) 4,800 HIV-infected control or Rab27a-silenced Jurkat cells present in a total of 80,000 cells (Donor cells, left) were added to GHOST cell cultures either allowing direct interaction or separated by a 0.2-µm pore filter (transwell). After 1.5 h of co-culture, cells were removed, and the percentage of GFP-positive GHOST cells was determined by FACS analysis 48 h later. FSC-H, forward scatter height. The boxes contain GFP-positive cells. Histograms show the means ± SD of three experiments performed in triplicates. \*, P \< 0.01; \*\*\*, P \< 0.001. KD, knockdown. Bars, 2 µm.](JCB_201409082_Fig5){#fig5}

To measure cell-to-cell transmission of HIV-1, the percentage of HIV-1--infected control or Rab27a-silenced cells at day 10 p.i. was determined by FACS. Because the percentage of HIV-1--infected cells was higher in control cells than in Rab27a-silenced cells, we normalized the percentage of HIV-1--infected cells in each condition by adding noninfected control cells to cultures of HIV-1--infected control cells to have 6% of HIV-infected cells in a total of 80,000 cells for each condition. ([Fig. 5 E](#fig5){ref-type="fig"}, left, donor cells). Cells were then added to cultures of GHOST cells (target), either in direct contact or separated by a filter membrane with pores that allow the passage of HIV-1 particles but not of cells. Silencing Rab27a expression impaired HIV-1 transmission both through cell--cell contact and through free viral particles ([Fig. 5 E](#fig5){ref-type="fig"}, right). These results indicate that Rab27a is required for the formation of virological synapses in both MDMs and CD4^+^ T cells and for HIV-1 cell-to-cell transmission in CD4^+^ T cells.

Rab27a controls the levels of PI(4,5)P~2~ in the PM of CD4^+^ T cells and in macrophage VCCs
--------------------------------------------------------------------------------------------

Targeting of Pr55^Gag^ to the PM is directed by PI(4,5)P~2~ ([@bib49]). Thus, we sought to investigate whether the reduction in Pr55^Gag^ association with the PM in Rab27a-silenced cells was caused by a reduction in PM levels of PI(4,5)P~2~. The intracellular distribution of PI(4,5)P~2~ was evaluated by LSCM in Jurkat cells transduced with a GFP-tagged pleckstrin homology (PH) domain derived from phospholipase Cδ1 (PH-GFP; [@bib66]). Staining of cell surface CD81 in nonpermeabilized cells was used to better define the localization of the PM. PH-GFP labeling of the PM was considerably reduced in Rab27a-silenced cells ([Fig. 6, A--C](#fig6){ref-type="fig"}). To assess global cellular levels of PI(4,5)P~2~ biochemically, the amount of \[^32^P\]orthophosphate incorporated into PI(4,5)P~2~ molecules was analyzed by thin layer chromatography (TLC; [Fig. 6 D](#fig6){ref-type="fig"}), confirming that the amount of \[^32^P\]-labeled PI(4,5)P~2~ was significantly lower in Rab27a-silenced cells ([Fig. 6 E](#fig6){ref-type="fig"}). Paralleling the results obtained in Jurkat cells, silencing of Rab27a in primary CD4^+^ T cells also resulted in a significant loss of PH-GFP staining at the PM ([Fig. 6, F and G](#fig6){ref-type="fig"}). Finally, PI(4,5)P~2~ distribution was analyzed in Rab27a-silenced MDMs. In agreement with previous studies ([@bib44]), in control cells, PI(4,5)P~2~ was enriched at the PM as well as in intracellular structures, which were also positive for CD81 ([Fig. 6 H](#fig6){ref-type="fig"}, top). In contrast, in Rab27a-silenced macrophages, PH-GFP and CD81, did not label any intracellular compartment ([Fig. 6, H and I](#fig6){ref-type="fig"}). These changes in PI(4,5)P~2~ distribution were accompanied by the presence of PM patches containing both PI(4,5)P~2~ and CD81. Examination of the phase contrast image of the same cell reveals that these patches were located in thicker parts of the PM, thus likely representing areas of stronger fluorescence signal.

![**Silencing of Rab27a reduces PI(4,5)P~2~ levels in the PM of CD4^+^ T cells and in VCCs of macrophages.** (A) LSCM visualization of PH-GFP in control and Rab27a-silenced Jurkat cells. Cell surface CD81 was labeled in nonpermeabilized cells and used as a reference of PM localization. Boxes indicate areas magnified on the right. (B) Representative single-cell intensity profile plots of the fluorescence of PH-GFP and CD81 at the PM quantified in a confocal slice along a line located on a representative segment of the cell (indicated with a scattered white line in the zoom shown in A). (C) Quantification of the localization of the PH-GFP signal predominantly at the PM or the cytosol in control and Rab27a-silenced cells was performed by blinded observers on a per-cell basis, in 200 cells of each condition. Data are expressed as percentages of cells in each category. (D) Incorporation of ^32^P in phosphoinositides was evaluated by TLC separation of lipid extracts from cells pulsed with \[^32^P\]orthophosphate. Shown is a representative autoradiograph. Positions of (phosphatidylinositol monophosphates \[PIP\]) and PI(4,5)P~2~ standards are indicated. (E) Quantification of the relative amounts of different phosphoinositides (*n* = 3). Error bars show SDs. (F) LSCM images of PH-GFP distribution in Rab27a-silenced primary CD4^+^ T cells isolated from blood. (G) Quantification of the localization of the PH-GFP signal predominantly at the PM or the cytosol of control and Rab27a-silenced CD4^+^ T cells. 200 cells were evaluated for each condition. (H) Representative LSCM images showing PH-GFP and CD81 distribution in control and Rab27a-silenced MDMs. (I) Quantification of the percentages of cells containing PH-GFP/CD81 double-positive structures in VCCs or at the peripheral PM. 90 cells were evaluated for each condition. (J and K) Restoring Rab27a expression in Jurkat cells expressing the 3′UTR Rab27a shRNA rescues PI(4,5)P~2~ levels at the PM. (J) Representative images of PH-mRFP distribution in Rab27a-silenced cells (using the 3′UTR shRNA) that were transduced (green cell) or not transduced with the Rab27a-encoding lentivirus. (K) Quantifications were performed by blinded observers on a per-cell basis, in ≥30 cells of each condition. Data are expressed as percentages of cells in each category. \*, P \< 0.01; \*\*\*, P \< 0.001. KD, knockdown. Bars: (A \[left\], F, H, and J) 2 µm; (A, right) 1 µm.](JCB_201409082_Fig6){#fig6}

Confirming the specificity of the phenotype described in this section, rescue experiments performed in Jurkat cells reverted the decrease in PM levels of PI(4,5)P~2~ ([Fig. 6 J](#fig6){ref-type="fig"}). Altogether, results presented in this section indicate that Rab27a regulates PI(4,5)P~2~ levels in the PM of CD4^+^ T cells and in VCCs of MDMs.

Rab27a controls PM levels of PI(4)P and the recruitment of PI4KIIα to the PM
----------------------------------------------------------------------------

To gain further mechanistic insight, the subcellular distribution of PI(4)P (a precursor in PI(4,5)P~2~ biosynthesis; [@bib20]) was analyzed in cells expressing the PI(4)P biosensor GFP-P4M ([@bib24]). In control Jurkat cells, PI(4)P was detected at the PM as well as in intracellular vesicles that likely represent endosomes and/or the Golgi complex ([Fig. 7 A](#fig7){ref-type="fig"}). Interestingly, in Rab27a-silenced cells, there was a selective loss of PM PI(4)P ([Fig. 7, A--C](#fig7){ref-type="fig"}). Because of its previously described association with late endosomes ([@bib57]; [@bib43]) and its role in PM PI(4)P production ([@bib70]; [@bib2]; [@bib52]; [@bib51]), we hypothesized that Rab27a was required for the recruitment of PI4KIIα to the PM from endosomes. Indeed, in control cells, PI4KIIα was located at the PM as well as in intracellular acidic (LysoTracker^+^) compartments ([Fig. 7 D](#fig7){ref-type="fig"}). In agreement with previous studies ([@bib5]; [@bib72]), we observed that PI4KIIα biochemically interacted with CD63 ([Fig. S5 A](http://www.jcb.org/cgi/content/full/jcb.201409082/DC1){#supp5}). Accordingly, we observed that both at the PM and in endosomes, PI4KIIα colocalized with CD63 ([Fig. 7 E](#fig7){ref-type="fig"}). Live-cell visualization of cells expressing GFP-PI4KIIa and mCherry CD63 evidenced that some CD63/PI4KIIα double-positive compartments presented rapid and long-range movements. In particular, we observed vesicles that approached the PM where they seemed to dock for several seconds ([Video 1](http://www.jcb.org/cgi/content/full/jcb.201409082/DC1){#supp6} and Fig. S5 B). Further suggesting a role of Rab27a in the trafficking of PI4KIIα, we observed that both molecules colocalized in intracellular structures (Fig. S5 C).

![**Rab27a controls PM levels of PI(4)P and the CD63-mediated recruitment of PI4KIIα to the PM.** (A) LSCM images of live control and Rab27a-silenced Jurkat cells transiently transfected with GFP-P4M-SidM plasmid and observed 24 h later. (B) Representative single-cell intensity profile plots of the mean fluorescence intensity of GFP-P4M-SidM quantified in the selected regions indicated with a white rectangle shown in A. (C) Quantification of the localization of the GFP-P4M-SidM signal predominantly at the PM or the cytosol in control and Rab27a-silenced cells was performed by blinded observers on a per-cell basis, in 200 cells of each condition. (D) LSCM of live control and Rab27a-silenced Jurkat cells transiently transfected with PI4KIIα-GFP plasmid and labeled with LysoTracker red. (E) LSCM of live control and Rab27a-silenced Jurkat cells transiently transfected with PI4KIIα-GFP and mCherry-CD63 plasmids. Manders correlation coefficient map is shown. Pseudocolored scale represents the contribution of each pixel to Manders colocalization coefficient (overlap coefficients for control and Rab27a-silenced cells: 0.74 ± 0.01 and 0.75 ± 0.02, respectively). Transmitted light images are shown on the right images of D and E. KD, knockdown. Bars, 2 µm.](JCB_201409082R_Fig7){#fig7}

Paralleling the alterations in CD63 distribution ([Fig. 2](#fig2){ref-type="fig"}), in Rab27a-silenced cells, PI4KIIα accumulated in enlarged acidic structures, whereas its localization at the PM was markedly reduced ([Fig. 7 D](#fig7){ref-type="fig"}). The biochemical interaction between CD63 and PI4KIIα was not altered in Rab27a-silenced cells (Fig. S5 A). Indeed, CD63 and PI4KIIα colocalized in enlarged endosomes, and both molecules were barely detected at the PM ([Fig. 7 E](#fig7){ref-type="fig"}). Live-cell visualization of CD63/PI4KIIα dynamics in Rab27a-silenced cells showed that the enlarged PI4KIIα-positive endosomes did not undergo long-range movements toward the cell periphery ([Video 2](http://www.jcb.org/cgi/content/full/jcb.201409082/DC1){#supp7} and Fig. S5 B). Altogether, these observations suggest that Rab27a controls the intracellular trafficking of CD63/PI4KIIα double-positive endosomes and the delivery of PI4KIIα to the PM, thus promoting PI(4)P and PI(4,5)P~2~ production at this location.

Slp2a is a Rab27a effector required for the delivery of PI4KIIα to the PM and for HIV-1 replication in CD4^+^ T cells
---------------------------------------------------------------------------------------------------------------------

We next sought to identify the Rab27a effector proteins that are required for HIV-1 production. A total of seven out of the nine Rab27a effector proteins analyzed were found to be expressed in Jurkat cells ([Table S1](http://www.jcb.org/cgi/content/full/jcb.201409082/DC1){#supp8}). The expression of each individual effector was silenced, and cells were then infected with HIV-1. Silencing of the genes EXPH5, SYTL2, and SYTL3, encoding the proteins Slac2b, Slp2a, and Slp3, respectively, reduced the extracellular release of p24 by ≥50% with ≥2 of the shRNA sequences that were used to target each gene ([Fig. 8 A](#fig8){ref-type="fig"}). The inhibition of HIV-1 replication was consistent with a reduction in the expression levels of EXPH5 and SYTL3, as determined by quantitative RT-PCR (qPCR; [Fig. 8 B](#fig8){ref-type="fig"}) and of Slp2a, as determined by immunoblotting ([Fig. 8 C](#fig8){ref-type="fig"}). We then selected one shRNA targeting each gene to analyze the kinetics of HIV-1 replication in large-scale cultures, using control and Rab27a-silenced cells for comparative purposes. The inhibition of HIV-1 replication in these experiments further confirmed the involvement of Slp2a, Slac2b, and Slp3 in HIV-1 replication ([Fig. 8 D](#fig8){ref-type="fig"}). Furthermore, LSCM visualization showed that silencing the expression of Slp2a, Slp3, and Slac2-b led to a diffuse intracellular Gag staining pattern accompanied by a dramatic reduction in the association of Pr55^Gag^ with the PM ([Fig. 8 E](#fig8){ref-type="fig"}).

![**Slp2a is a Rab27a effector required for PM delivery of PI4KIIα and HIV-1 assembly.** (A) p24 production by Jurkat cells transduced with different shRNAs targeting Rab27 effector genes and subsequently infected with a VSV-G--pseudotyped HIV-1 strain was evaluated at day 4 p.i. Data are the means ± SD of three independent experiments. Solid lines and dashed lines indicate 100% and 50%, respectively, of p24 production by control cells. (B) Inhibition of gene expression of EXPH5 and SYTL3 was determined by qPCR (*n* = 2). (C) Inhibition of Slp2a expression was determined by immunoblotting. (D) Kinetics of HIV-1 (strain IIIB; inoculum: 100 ng/ml) production by Jurkat cells stably transduced with control shRNA (closed circles), SYTL2 shRNA 1 (open squares), EXPH5 shRNA1 (open circles), and SYTL3 shRNA 1 (open triangles). Rab27a-silenced cells were included for comparative purposes (closed squares). One representative experiment of two performed in triplicates is shown. (E) Intracellular distribution of Gag in control or Slac2-b--, Slp2a-, and Slp3-silenced cells was analyzed by LSCM at day 7 p.i. (F) LSCM visualization of cells transiently transfected with dsRed-Rab27a and Slp2a-GFP. (G--J) LSCM of live control and Rab27a-silenced cells stably expressing CD63-GFP (G), PI4KIIa-GFP (H), GFP-P4M (I), and PH-GFP (J). Representative confocal images (left) and transmitted light images (right) are shown. Quantifications were performed by blinded observers on a per-cell basis, in ≥50 cells of each condition. (K) LSCM of live Slp2a-silenced Jurkat cells transiently transfected with PI4KIIα-GFP and mCherry-CD63 plasmids. Error bars show SDs. KD, knockdown. Bars, 2 µm.](JCB_201409082_Fig8){#fig8}

We then decided to further analyze the mechanistic basis of the inhibition of HIV-1 replication by Slp2a, an effector that has been previously shown to play an important role in vesicle docking, in particular in CD8^+^ T lymphocytes ([@bib41]). First, we observed that Rab27a and the hematopoietic isoform of Slp2a, Slp2a-hem, colocalized on the same intracellular vesicular structures ([Fig. 8 F](#fig8){ref-type="fig"}). We next analyzed the subcellular distribution of CD63, PI4KIIα, PI(4)P, and PI(4,5)P~2~ in Slp2a-silenced cells. An intracellular accumulation of CD63-positive compartments concurrent with a decrease in PM levels of CD63 was observed ([Fig. 8 G](#fig8){ref-type="fig"}). Furthermore, we observed that PI4KIIα levels at the PM were dramatically reduced and that the enzyme accumulated at intracellular structures ([Fig. 8 H](#fig8){ref-type="fig"}). Consistent with a reduction in PM levels of PI4KIIα, PM levels of PI(4)P ([Fig. 8 I](#fig8){ref-type="fig"}) and PI(4,5)P2 ([Fig. 8 J](#fig8){ref-type="fig"}) were reduced.

Analysis of CD63 and PI4KIIα interaction showed that both molecules still interacted in Slp2a-silenced cells ([Figs. 8 K](#fig8){ref-type="fig"} and S5 A). Interestingly, live-cell visualization showed that, as in the case of Rab27a-silenced cells, both molecules were present in enlarged endosomes that exhibited limited movement. Moreover, the presence of both molecules at the PM was markedly reduced ([Video 3](http://www.jcb.org/cgi/content/full/jcb.201409082/DC1){#supp9} and Fig. S5 B). Altogether, these observations show that Rab27a and Slp2a function together in the trafficking of PI4KIIα/CD63-positive endosomes toward the PM, thus contributing to the generation of PI(4)P and a pool of PI(4,5)P~2~ that is required for HIV-1 assembly.

Discussion
==========

In this study, we show that in CD4^+^ T cells, Rab27a controls the intracellular trafficking of PI4KIIα-positive late endosomes and the recruitment of this enzyme to the PM. Therefore, Rab27a promotes the production of PM PI(4)P and a pool of PI(4,5)P~2~ required for Pr55^Gag^ membrane association and HIV-1 assembly. Moreover, we show that Rab27a regulates PI(4,5)P~2~ production in the VCCs of macrophages. These results provide new information about the function of Rab27a and reveal that a common pathway regulated by Rab27a is required for HIV-1 production in the two principal target cells of HIV-1 infection.

The main precursor for PI(4,5)P~2~ synthesis at the PM is PI(4)P, a product of the activity of a PI4-kinase acting on phosphatidylinositol ([@bib20]). Although in some cell types, PI(4)P production at the PM is performed by PI4KIIIα ([@bib47]), PI4KIIα has also been shown to control cellular levels of PI(4,5)P~2~ ([@bib51]; [@bib14]; [@bib33]). Indeed, despite the fact that in several cell types PI4KIIα localizes primarily to the trans-Golgi network and endosomes ([@bib69]; [@bib57]; [@bib2]; [@bib43]), a portion of PI4KIIα can be recruited to the PM ([@bib70]; [@bib52]). In line with these observations, our results not only show that PI4KIIα is found in late endosomes but also that, by regulating the trafficking of these endosomes, Rab27a allows the recruitment of the enzyme to the PM of CD4^+^ T cells. Consequently, Rab27a induces PI(4,5)P~2~ production, thus favoring the recruitment of Pr55^Gag^. After its association with the PM, Pr55^Gag^ functions as a microdomain-organizing factor, inducing the coalescence of preformed PM domains, such as TEMs and lipid rafts ([@bib36]; [@bib25]; [@bib34]), creating a novel virus--induced PM domain used as a platform for HIV-1 assembly and budding. Therefore, our results suggest that HIV-1 assembly is functionally coupled to the trafficking and fusion of late endosomes with the PM.

The cytosolic accumulation of Pr55^Gag^ in Rab27a-silenced cells is in agreement with previous studies showing that, in CD4^+^ T cell lines, depletion of PI(4,5)P~2~ by overexpression of phosphoinositide 5-phosphatase IV induces redistribution of Pr55^Gag^ to a predominantly cytosolic localization ([@bib46]). In contrast, depletion of PM PI(4,5)P~2~ in HeLa cells induces Gag accumulation in CD63-positive MVEs ([@bib49]). Although the basis for these cell type--dependent differences is not clear, these observations indicate that the role played by endosomes in Gag membrane targeting and HIV-1 assembly is different in CD4^+^ T cells and MDMs, as compared with HeLa cells. Along these lines, by using viral variants harboring mutations that block Gag-PI(4,5)P~2~ binding and target Gag to MVEs, it has been suggested that CD4^+^ T cells and MDMs rely more heavily on an endosome-to-PM trafficking pathway, as compared with HeLa cells ([@bib30]). In agreement with these results, we observed that whereas inhibition of Rab27a expression in HeLa cells induces a profound decrease in the docking of MVEs to the PM ([@bib50]), the reduction in PI(4,5)P~2~ levels at the PM and, consequently, HIV-1 assembly are not perturbed in this model cell line (unpublished data). The existence of different or alternative pathways of PI(4,5)P~2~ production and HIV-1 assembly in HeLa versus hematopoietic cells will be addressed in future studies.

Despite the unequivocal presence of tetraspanins at HIV-1 exit sites, their role during HIV-1 assembly remains an open question ([@bib12]; [@bib56]; [@bib22]; [@bib35]; [@bib37]). The difficulty in defining the role played by tetraspanins during the late stages of HIV-1 replication is probably a result of the fact that compensatory mechanisms are likely to take place between the more than 33 members of the tetraspanin family. Our results show that by promoting the fusion of late endosomes with the PM, Rab27a controls the levels of CD63 (and very likely other endosomal tetraspanins) at this location. The biochemical association between CD63 and PI4KIIα suggests the localized production of PI(4)P at TEMs followed by the subsequent production of PI(4,5)P~2~. These findings could thus represent the biochemical basis of the association of Pr55^Gag^ with TEMs.

The different roles played by Rab27 are determined by the interaction with a different set of downstream effectors specialized in different functions. Herein, we found that in Jurkat cells, silencing of three different effectors, Slac2b, Slp2a, and Slp3, reduces Pr55^Gag^ membrane association and HIV-1 replication. These results suggest a nonredundant and cooperative mode of action, in which the three Rab27 effectors work jointly in the Rab27a-controlled pathway. A similar mode of interaction has been observed in neuroendocrine PC12 cells, in which four Rab27 effectors, Slp4-a, Slac2-c, Rabphilin, and Noc2 contribute to the docking of granules to the PM ([@bib17]; [@bib64], [@bib65]). Further analysis of the role played by Slp2a allowed us to conclude that silencing this Rab27a effector phenocopies Rab27a-silenced cells, resulting in a reduction in PM levels of CD63, PI4KIIa, PI(4)P, and PI(4,5)P~2~. These results, together with previous studies showing that Slp2a is a critical docking factor ([@bib40]), suggest that by recruiting Slp2a to CD63^+^ endosomes, Rab27a promotes the docking of these endosomes to the PM, allowing their fusion and the consequent delivery of PI4KIIa.

In conclusion, this study demonstrates that Rab27a regulates PI(4,5)P~2~ levels at the PM of CD4^+^ T cells and in macrophage VCCs. Thus, Rab27a controls membrane association of Pr55^Gag^ and, consequently, is required for HIV-1 replication.

Materials and methods
=====================

Cell lines, plasmids, lentiviral vectors, and HIV-1 viral strains
-----------------------------------------------------------------

The human CD4^+^ T cell line Jurkat clone E6.1, the HIV-1 infection reporter human osteosarcoma cell line GHOST X4/R5, the HIV-1 BaL strain (using CCR5 coreceptor), and the HIV-1 IIIB strain (using CXCR4 coreceptor) were obtained from the AIDS Reagent Program, Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health. HEK 293T cells were obtained from ATCC (CRL-11268).

The following plasmids were used: pEGFP-bos-CD63 and mCherry-bos-CD63 encoding full-length CD63 in pEGFP-C1-bos or pmCherry-C1-bos backbone, respectively, under the Bos promoter (provided by G. Griffiths, Cambridge Institute for Medical Research, Cambridge, England, UK; [@bib6]); GFP-P4M-SidM encoding the P4M domain from *Legionella pneumophila* fused to EGFP in the pEGFP-C1 backbone under cytomegalovirus (CMV) promoter (Addgene plasmid 51469; [@bib24]); pEGFP-C3-Rab27a encoding full-length Rab27a in the pEGFP-C3 backbone under the CMV promoter ([@bib26]); pEGFP-N1-PI4K2A encoding full-length PI4K2A in the pEGFP-N1 backbone under the CMV promoter (provided by T. Balla, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD; [@bib32]); pEGFP-C1-Slp2a-hem encoding the hematopoietic form of Slp2-a in the pEGFP-C1 backbone under the CMV promotor (provided by G. de Saint Basile, Centre de Référence pour les Déficits Immunitaires Héréditaires, Paris, France; [@bib41]); Rab27a-2A-GFP encoding full-length Rab27a fused to a 2A peptide sequence from *Thosea asigna* virus followed by EGFP in pcDNA HIV SIN PZ-CG-FRW-DNP (Z-368) under the CMV promoter (provided by M. Zhang and R. Cron, University of Alabama at Birmingham, Birmingham, AL); pBR-NL4.3-IRES-EGFP-Nef^+^ encoding full-length HIV-1 in the pBR322 backbone under the control of viral long terminal repeat promoter (provided by F. Kirchhoff, Institute of Molecular Virology, Ulm University Medical Center, Ulm, Germany; [@bib59]); PH-GPF encoding the PH domain of phospholipase C δ1 subunit fused to GFP in pWPT-GFP under the EF1α promoter (provided by R. Galandrini, Istituto Pasteur-Fondazione Cenci-Bolognetti, Fondazione Eleonora Lorillard Spencer Cenci, Sapienza University, Rome, Italy; [@bib42]).

Lentiviruses were produced as described elsewhere ([@bib45]). In brief, 2.5 × 10^3^ HEK293T were seeded on a flat-bottom 96-well plate. 24 h later, cells were transfected with a mix of 100 ng pCMV-dR8.2 DVpr, 100 ng of the target's specific shRNA in the pLKO.1 backbone, and 10 ng pCMV--VSV-G per well, using X-tremeGENE HP DNA transfection reagent (Roche), following the manufacturer's recommendations. 24 h later, medium was replaced, and supernatants containing lentiviral particles were collected at 48 and 72 h after transfection, precleared by centrifugation, aliquoted, and stored at −80°C.

The sequences of the shRNA used are: RAB27A\#1, 5′-CCGGCGGATCAGTTAAGTGAAGAAACTCGAGTTTCTTCACTTAACTGATCCGTTTTT-3′; RAB27A\#2, 5′-CCGGGCTGCCAATGGGACAAACATACTCGAGTATGTTTGTCCCATTGGCAGCTTTTT-3′; RAB27A targeting the 3′UTR region, 5′-GTACCGGGATCTTCTCTATGATTGATACCTCGAGGTATCAATCATAGAGAAGATCTTTTTTG-3′; MLPH\#1, 5′-CCGGCCTTTAGGACAATGTTGTGTACTCGAGTACACAACATTGTCCTAAAGGTTTTTTG-3′; MLPH\#2, 5′-CCGGGTCTTCTGAGAGTCAGATCTTCTCGAGAAGATCTGACTCTCAGAAGACTTTTTTG-3′; MLPH\#3, 5′-CCGGCTGATCTGTGAGAAACAGCTACTCGAGTAGCTGTTTCTCACAGATCAGTTTTTTG-3′; MLPH\#4, 5′-CCGGGATCGGAAATCAGTGTACCGACTCGAGTCGGTACACTGATTTCCGATCTTTTTTG-3′; MLPH\#5, 5′-CCGGCAGTACAACAGGACCACAGATCTCGAGATCTGTGGTCCTGTTGTACTGTTTTTTG-3′; EXPH5\#1, 5′-CCGGCCGCTTAATATCTATGAGGATCTCGAGATCCTCATAGATATTAAGCGGTTTTTTG-3′; EXPH5\#2, 5′-CCGGCCGCACACAGATAAATCCAATCTCGAGATTGGATTTATCTGTGTGCGGTTTTTTG-3′; EXPH5\#3, 5′-CCGGCCCAAACTAGAAGAAGTTCTTCTCGAGAAGAACTTCTTCTAGTTTGGGTTTTTTG-3′; EXPH5\#4, 5′-CCGGCCTCTATCGTTCAAAGAGTTTCTCGAGAAACTCTTTGAACGATAGAGGTTTTTTG-3′; EXPH5\#5, 5′-CCGGGCCAAGAGAAAGGACATTCTTCTCGAGAAGAATGTCCTTTCTCTTGGCTTTTTTG-3′; SYTL1\#1, 5′-CCGGCCTGGACACTTACGTACAATGCTCGAGCATTGTACGTAAGTGTCCAGGTTTTTG-3′; SYTL1\#2, 5′-CCGGGGCGGTGAAGAAACGGAATCTCTCGAGAGATTCCGTTTCTTCACCGCCTTTTTG-3′; SYTL1\#3, 5′-CCGGTGACCTTGTCCGAGCGTCTATCTCGAGATAGACGCTCGGACAAGGTCATTTTTG-3′; SYTL1\#4, 5′-CCGGTCAACGAGACTCTCCGGTACTCTCGAGAGTACCGGAGAGTCTCGTTGATTTTTG-3′; SYTL1\#5, 5′-CCGGACATCTTTCTGGGCGAAGTTGCTCGAGCAACTTCGCCCAGAAAGATGTTTTTTG-3′; SYTL2\#1, 5′-CCGGTAACGAAATACTGCGGTATAACTCGAGTTATACCGCAGTATTTCGTTATTTTTG-3′; SYTL2\#2, 5′-CCGGCTTAGCAGCAGCGGATGTAAACTCGAGTTTACATCCGCTGCTGCTAAGTTTTTG-3′; SYTL2\#3, 5′-CCGGATTTGGCATCGGGATACATTTCTCGAGAAATGTATCCCGATGCCAAATTTTTTG-3′; SYTL2\#4, 5′-CCGGGTCGCAGAAAGATACTCAAAGCTCGAGCTTTGAGTATCTTTCTGCGACTTTTTG-3′; SYTL2\#5, 5′-CCGGTCAACCACACTATGGTGTATGCTCGAGCATACACCATAGTGTGGTTGATTTTTG-3′; SYTL3\#1, 5′-CCGGGAGAAATACGAAGACAGCGTTCTCGAGAACGCTGTCTTCGTATTTCTCTTTTTTG-3′; SYTL3\#2, 5′-CCGGCGGAGAGTGTTTCTTGGAGAACTCGAGTTCTCCAAGAAACACTCTCCGTTTTTTG-3′; SYTL3\#4, 5′-CCGGGCACCTTGAACTCATTTGTTACTCGAGTAACAAATGAGTTCAAGGTGCTTTTTTG-3′; SYTL3\#5, 5′-CCGGCAAATGCTCTACTAACCCTATCTCGAGATAGGGTTAGTAGAGCATTTGTTTTTTG-3′; MYRIP\#1, 5′-CCGGGCCAAATAAGTGCAAAGATTTCTCGAGAAATCTTTGCACTTATTTGGCTTTTTG-3′; MYRIP\#2, 5′-CCGGCCCAGGTACAAACCATAGATACTCGAGTATCTATGGTTTGTACCTGGGTTTTTG-3′; MYRIP\#3, 5′-CCGGGCTTCGACATTCTAGGAGGAACTCGAGTTCCTCCTAGAATGTCGAAGCTTTTTG-3′; MYRIP\#4, 5′-CCGGGCTGTACGAGTTAGCAATGAACTCGAGTTCATTGCTAACTCGTACAGCTTTTTG-3′; MYRIP\#5, 5′-CCGGCCTGCAGAAGATTATACGAAACTCGAGTTTCGTATAATCTTCTGCAGGTTTTTG-3′; RPH3AL\#1, 5′-CCGGGGCTATCTCCGTTGCTATATTCTCGAGAATATAGCAACGGAGATAGCCTTTTTG-3′; RPH3AL\#2, 5′-CCGGAGGGACCGGAAAGGCGACAAACTCGAGTTTGTCGCCTTTCCGGTCCCTTTTTTG-3′; RPH3AL\#4, 5′-CCGGTAGAGGACAGACTCCCATCCACTCGAGTGGATGGGAGTCTGTCCTCTATTTTTG-3′; RPH3AL\#5, 5′-CCGGCAGGAAGAAAGTCTGCACCAACTCGAGTTGGTGCAGACTTTCTTCCTGTTTTTG-3′; RPH3AL\#6, 5′-CCGGGCAGTGAGCAAAGAGAGGTCTCTCGAGAGACCTCTCTTTGCTCACTGCTTTTTG-3′; SYTL4\#1, 5′-CCGGCCTCACTACAACCATACATTTCTCGAGAAATGTATGGTTGTAGTGAGGTTTTTG-3′; SYTL4\#2, 5′-CCGGCGGGACACTGTTAATCCACTACTCGAGTAGTGGATTAACAGTGTCCCGTTTTTG-3′; SYTL4\#3, 5′-CCGGCCTCCCTTTACATGGAAAGATCTCGAGATCTTTCCATGTAAAGGGAGGTTTTTG-3′; SYTL4\#4, 5′-CCGGCGCCAAGGAAATAGAGTTGAACTCGAGTTCAACTCTATTTCCTTGGCGTTTTTG-3′; SYTL4\#5, 5′-CCGGGAGTACACTAAATCTGTGATACTCGAGTATCACAGATTTAGTGTACTCTTTTTG-3′; UNC13D\#1, 5′-CCGGGCTTTGCTACATGAACACCAACTCGAGTTGGTGTTCATGTAGCAAAGCTTTTTTG-3′; UNC13D\#2, 5′-CCGGGAGACCTTCATCCTGGAGTTTCTCGAGAAACTCCAGGATGAAGGTCTCTTTTTTG-3′; UNC13D\#3, 5′-CCGGCTTCATGATTACCGTCAAGTTCTCGAGAACTTGACGGTAATCATGAAGTTTTTTG-3′; UNC13D\#4, 5′-CCGGGATCTTCCACAATACCCTCAACTCGAGTTGAGGGTATTGTGGAAGATCTTTTTTG-3′; UNC13D\#5, 5′-CCGGGATGTGCAAGATGAAGGCCTTCTCGAGAAGGCCTTCATCTTGCACATCTTTTTTG-3′; TBC1D10A\#1, 5′-CCGGGAGTGAGGACACCTACTTGTACTCGAGTACAAGTAGGTGTCCTCACTCTTTTTTG-3′; TBC1D10A\#2, 5′-CCGGCAAGGTGAAGTTACAGCAGAACTCGAGTTCTGCTGTAACTTCACCTTGTTTTTTG-3′; TBC1D10A\#3, 5′-CCGGCCATATAACTACACGGTTCATCTCGAGATGAACCGTGTAGTTATATGGTTTTTTG-3′; TBC1D10A\#4, 5′-CCGGGTTCCCATTCCATGAGATGTTCTCGAGAACATCTCATGGAATGGGAACTTTTTTG-3′; and TBC1D10A\#5, 5′-CCGGCGCTCCTCTATATGACAGAATCTCGAGATTCTGTCATATAGAGGAGCGTTTTTTG-3′.

Antibodies
----------

The following antibodies were used: phycoerythrin (PE)-labeled mouse anti--human CD81 (BD); PE-labeled mouse anti--human CD63 (Invitrogen); rabbit anti--human Rab27a and rabbit anti--human β-actin (Synaptic Systems); PE-labeled mouse anti--humanCD317/Tetherin (eBioscience); FITC-labeled mouse anti--HIV-1 p24 (KC57-FITC; Beckman Coulter); rabbit anti--HIV-1 gp41 (Fitzgerald); Alexa Fluor 594--labeled donkey anti--mouse, Alexa Fluor 488--labeled donkey anti--mouse, biotin-labeled donkey anti--human, and Alexa Fluor 594--labeled donkey anti--rabbit (Jackson ImmunoResearch Laboratories, Inc.); rabbit anti--human Slp2-a (provided by M. Fukuda, Tohoku University, Katahira, Miyagi Prefecture, Japan) was obtained by immunizing rabbits with GST-Slp2-a-SHD followed by affinity purification by exposure to antigen-bound Affi-Gel 10 beads ([@bib27]); rabbit anti--rat PI4KIIα (full length; [@bib23]) was provided by P. De Camilli (Yale University, New Haven, CT); and recombinant human anti--HIV-1 gp120 monoclonal antibody (2G12, produced in CHO cells and subsequently purified by protein A affinity chromatography) from H. Katinger ([@bib8]; [@bib63]) and mouse anti--HIV-1 p24 monoclonal antibody (clone 183-H12-5C) from B. Chesebro ([@bib13]) were obtained through the National Institutes of Health AIDS Reagent Program, Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health.

Patient with GS
---------------

The pediatric patient with GS type 2 carries a homozygous RAB27A exon 3 and 4 deletion leading to a frameshift and a premature stop codon. PBMCs were obtained from the patient and the corresponding age-matched controls, who had provided written informed consent in accordance with procedures at Institut National de la Santé et de la Recherche Médicale (Paris, France).

Preparation of viral stocks
---------------------------

The HIV-1 BaL isolate was propagated onto primary macrophages and collected from the culture supernatants. The HIV-1 IIIB isolate was obtained from H9/HTLV-IIIB supernatants ([@bib53]). The viruses were concentrated by ultracentrifugation at 28,000 rpm for 90 min at 4°C (L7-65 ultracentrifuge; Beckman Coulter), and the virus pellet was suspended in RPMI 1640 medium. The levels of p24 antigen were determined by ELISA (InnoGenetics), and virus input into assays was a function of p24 antigen concentration.

Degranulation assay and CD63 cell surface translocation
-------------------------------------------------------

For degranulation assays, 2 × 10^5^ control or Rab27a-silenced primary CD4^+^ T cells were cultured at 37°C in 200 µl complete RPMI containing 10 µM monensin and 5 µg/ml FITC-conjugated anti-CD63 or isotype control. When indicated, cells were stimulated for 20 min with 25 ng/ml PMA (Sigma-Aldrich) and 1 µg/ml ionomycin (Sigma-Aldrich). Cells were washed and analyzed by FACS.

HIV-1 infection
---------------

Macrophages (5 × 10^4^/0.1 ml) were infected with HIV-1 BaL strain (50 ng/ml) for 1.5 h at 37°C. Cells were subsequently washed and incubated for different periods. Jurkat cells, PBMCs, and purified CD4^+^ T lymphocytes (3 × 10^4^/0.1 ml) were infected by the addition of either HIV-1 IIIB strain (50 ng p24/ml; low MOI) or spinoculated with VSV-G--pseudotyped NL4-3-IRES-EGFP (50 ng p24/ml \[low MOI\] or 200 ng p24/ml \[high MOI\]) in the presence of 8 µg/ml of polybrene.

In the screening for Rab27a effector proteins, the number of puromycin-resistant Jurkat cells transduced with the different shRNAs was measured using CellTiter 96 AQueous Non-Radioactive Cell Proliferation Assay (Promega). An equal number of cells were then infected with VSV-G--pseudotyped NL4-3-IRES-EGFP (20 ng p24/ml) to ensure a uniform MOI in all conditions.

Quantification of HIV-1 production
----------------------------------

HIV-1 p24 released into the cell culture supernatants was quantified using the Innotest HIV-1 Ag mAb Screening 3 kit (InnoGenetics). The number of living cells present in each well was evaluated using CellTiter 96 AQueous Non-Radioactive Cell Proliferation Assay.

Infectivity assay
-----------------

For infectivity assays, control and Rab27a-silenced cells were infected with HIV-1 strain IIIb. At day 10 after infection, cell culture supernatants were collected, and their content of p24 was determined by ELISA to allow the normalization for equal amounts of p24. The volume of supernatant equivalent to 10 ng p24 was incubated with 20,000 GHOST cells for 48 h, and the percentage of GFP-positive GHOST cells was determined by FACS analysis.

Lentiviral transduction, gene silencing, and transfection of Jurkat cells
-------------------------------------------------------------------------

A total of 30,000 Jurkat cells were transduced with lentiviral vectors by spinoculation (2,200 rpm at 90 min for 37°C) in the presence of 8 µg/ml of polybrene. After 48 h, transduced cells were selected by the addition of 3 µg/ml puromycin. Transfection of Jurkat cells was performed using X-tremeGENE HP DNA (Roche) following the manufacturer's instruction.

Primary cells transduction and gene silencing
---------------------------------------------

To silence gene expression in macrophages, monocytes were isolated from buffy coats of healthy anonymous donors from the Blood Center of the Mendez Hospital in Buenos Aires, Argentina. Cells were transduced with the corresponding lentiviral vector together with virus-like particles containing the protein VPx from simian immunodeficiency virus (provided by N. Manel, Institut Curie, Paris, France) in the presence of 30 ng/ml rHuGM-CSF and 2.5 µg/ml polybrene for 5 d following a recently published protocol ([@bib58]). Transduced cells were selected by the addition of 30 µg/ml puromycin. To silence gene expression in primary T lymphocytes, either PBMCs or isolated CD4^+^ T lymphocytes (purified by using a CD4^+^ T Cell Isolation kit \[Miltenyi Biotec\]) were seeded at 2 × 10^6^ cells/ml and stimulated with either 1 µg/ml phyto-HA or with anti-CD3/CD28 beads for 3 d in culture medium supplemented with 10 U/ml IL-2. Subsequently, cells were spinoculated as described in the previous section. After spinoculation, 5 ng/ml rIL-2 was added and refreshed every 3 d.

HIV-1 attachment and entry
--------------------------

For HIV attachment and entry measurements, 50,000 Jurkat cells were infected with HIV-1 strain IIIb (50 ng/ml p24) for 1.5 h at 4°C (attachment) or 37°C (attachment + entry). Cells were then extensively washed (five times) to remove unbound viral input and lysed with radioimmunoprecipitation assay buffer. Total cell protein was calculated using bicinchoninic acid, and all samples were normalized for protein content before quantification of cell-associated p24 by ELISA. Viral attachment (4°C) corresponds to p24 amount measured in samples kept at 4°C, and viral entry corresponds to the difference between p24 from samples kept at 37°C and the ones at 4°C.

Single cycle viral entry assay
------------------------------

A total of 30,000 Jurkat cells were infected with two doses of HIV-1 strain IIIb (50 and 500 ng/ml) for 6 h at 37°C. Cells were then washed to remove extracellular virions, and 5 µM AZT (zidovudine) was added to the culture medium to prevent secondary replication cycles and maintained throughout the study. Alternatively, cells were treated with AZT before HIV-1 infection to evaluate the efficiency of the drug to inhibit HIV-1 replication. Viral entry was assessed by quantifying the percentage of HIV-1--infected cells at 48 h p.i.

HIV-1 release assay
-------------------

3 × 10^4^/0.1 ml Jurkat cells were spinoculated with a high MOI of VSV-G--pseudotyped HIV-1. 48 h later, 1 ml cell culture supernatants were collected, ultracentrifuged (100,000 g; 90 min), and resuspended in 20 µl of immunoblot loading buffer. Cells were extensively washed and lysed. 20 µg of cell lysate and the totality of the pelleted supernatant were analyzed by immunoblotting using p24 antibodies and actin as a loading control for the cell lysates.

Rab27a shRNA rescue experiments
-------------------------------

To rescue the Rab27a knockdown phenotype, exogenous Rab27a was expressed in Jurkat cells in which endogenous Rab27a expression was silenced by using an shRNA targeting the 3′UTR of the Rab27a gene. Expression of exogenous Rab27a was achieved by transducing the cells with a lentiviral vector encoding human Rab27a fused to a 2A peptide sequence from *T. asigna* virus followed by GFP, thus allowing simultaneous expression of Rab27a and GFP. Cells expressing the exogenous Rab27a were identified by visualizing GFP expression in microscopy experiments. Alternatively, to analyze HIV-1 replication, GFP-expressing cells were FACS sorted and subsequently infected with HIV-1.

Cell lysates and immunoblot
---------------------------

Cells were lysed in precooled radioimmunoprecipitation assay buffer (1% Triton X-100, 0.1% SDS, 50 mM Tris, pH 7.5, 150 mM NaCl, and 0.5% sodium deoxycholate), supplemented with a cocktail of antiproteases (Roche), and cleared from nuclei by centrifugation at 15,000 *g* for 5 min. Equal amounts of protein extracts were separated on 4--12% SDS-PAGE, blotted on Polyvinylidene Fluoride Transfer Membrane (Thermo Fisher Scientific). Blots were revealed using SuperSignal West Pico Chemiluminescent Substrate (Thermo Fisher Scientific). Intensity of the bands was quantified using the software ImageJ (National Institutes of Health).

Cell fractionation
------------------

Subcellular fractionation was performed using the Qproteome Cell Compartment kit, according to the manufacturer's instructions (QIAGEN). Alternatively, cell fractions were isolated by differential centrifugation as described previously ([@bib15]). In brief, 10^7^ Jurkat cells were washed twice in PBS and attached extracellular virus was eliminated by incubating the cells with trypsin for 5 min at 37°C. After washing, cells were resuspended in 250 mM sucrose, 50 mM Tris-HCl, pH 7.4, and 5 mM MgCl~2~ containing protease inhibitor cocktail (Roche). This suspension was passed 40 times through a 29-guage needle to lyse the cells, centrifuged to eliminate nuclei and cells debris, and then ultracentrifuged for 1 h at 100,000 *g*. The supernatant of this ultracentrifugation represents the cytosolic proteins, and the pellet represents the membrane-bound proteins. This pellet was resuspended in 0.5 ml of 20 mM Tris-HCl, 0.4 M NaCl, 15% glycerol, and 1.5% Triton X-100, incubated for 1-h shaking at 1,400 rpm and 4°C, and centrifuged at 9,000 *g* for 30 min. The supernatant contained the isolated membrane proteins.

Immunoprecipitation of GFP-CD63
-------------------------------

For immunoprecipitation of GFP-CD63, 10^7^ GFP-CD63--transfected cells were lysed in immunoprecipitation buffer (1% Brij 99, 10 mM Tris/HCl, pH 7.4, 150 mM NaCl, and 5 mM EDTA, with Roche protease inhibitor cocktail) for 1 h at 4°C. Precleared supernatants were then immunoprecipitated with GFP-Traps or uncoated agarose beads (as control for unspecific bound) according to manufacturer's instructions (ChromoTek). Coprecipitation of PI4KIIα was revealed by immunoblotting.

qPCR
----

RNAs were isolated with TRIzol reagent (Life Technologies), and 200-ng RNAs were reverse transcribed with M-MLV Reverse transcription (Invitrogen). 1/10th cDNA was used for each PCR reaction, performed with SYBR green (Applied Biosystems) on a real-time thermal cycler (PRISM 7500; Applied Biosystems). Cycle thresholds (Ct's) were normalized to the Ct of GAPDH, and fold enrichments were calculated as compared with the values from control shRNA-transduced cells.

Cell-to-cell transmission assay
-------------------------------

Jurkat cells (donor cells) were infected with the HIV-1 IIIB strain. At day 10 p.i, the percentage of infected cells was determined by intracellular staining of p24 antigen followed by FACS analysis. To have equal numbers of control and Rab27a-silenced HIV-1--infected Jurkat cells, cells were diluted with noninfected control or Rab27a-silenced cells, respectively, to have a total of 4,800 HIV-1--infected donor cells present in a total of 80,000 cells (6%) for each category. Next, cells were added to wells containing 30,000 adherent GHOST cells (target). Donor and target cells were co-cultured at 37°C for 3 h before Jurkat cells were removed by extensive washes. HIV-1 transmission was evaluated 48 h later by analyzing the percentage of GFP-expressing GHOST cells. Alternatively, donor and target cells were separated by a 0.2-µm-diameter pore to allow viral transmission without cell-to-cell contact.

Flow cytometry
--------------

For surface labeling, cells were stained with antibodies diluted in PBS--0.5% BSA on ice. For intracellular staining, cells were fixed and permeabilized using Cytofix/Cytoperm reagents (BD) and stained with antibodies diluted in permeabilization buffer. Cells were acquired on a FACSCanto (BD) and analyzed using FACSDiva software (BD).

Fluorescence microscopy
-----------------------

10^5^ cells were seeded on poly-[l]{.smallcaps}-lysine--coated glass coverslips for 60 min, fixed in 4% paraformaldehyde, quenched with 0.1 M glycine, permeabilized in PBS--0.2% BSA--0.05% saponin, and incubated with primary antibodies, which were subsequently detected with Alexa Flour 594--labeled donkey anti--mouse, Alexa Fluor 488--labeled donkey anti--mouse, or Alexa Fluor 594--labeled donkey anti--rabbit (Jackson ImmunoResearch Laboratories, Inc.) secondary antibodies, as indicated. The coverslips mounted with Fluoromount-G (SouthernBiotech) were examined under a confocal microscope (FluoView FV1000; Olympus) using a Plan Apochromat 60× 1.42 NA oil immersion objective. Images were analyzed using the FV10-ASW software (Olympus). In [Figs. 3 C](#fig3){ref-type="fig"}, [4 C](#fig4){ref-type="fig"}, [5](#fig5){ref-type="fig"}, and [6 (E, F, and H)](#fig6){ref-type="fig"}, levels were adjusted using Photoshop 7 (Adobe) for better visualization according to the guidelines for the presentation of digital data.

Fluorescence images of live or fixed cells shown in [Figs. 2](#fig2){ref-type="fig"}, [6 A](#fig6){ref-type="fig"}, [7](#fig7){ref-type="fig"}, [8 (F--I)](#fig8){ref-type="fig"}, S5 B, and Videos 1--3 were acquired in a spectral confocal microscope (FluoView FV1000; acquisition software FV10-ASW 2.0), at room temperature, using a 60× U Plan S Apochromat, NA 1.35 oil immersion objective, in RPMI 1640 medium supplemented with 10% FCS and 10 nM Hepes. Images and videos were analyzed using FIJI (National Institutes of Health) and Matlab (The MathWorks, Inc.) software, respectively.

In [Figs. 3 A](#fig3){ref-type="fig"} and [5 C](#fig5){ref-type="fig"}, images were acquired at room temperature using a motorized upright wide-field microscope (DMRA2; Leica) equipped for image deconvolution. Acquisition was performed using a 100× objective (Plan Apochromat HCX, 1.4 NA) and a high-sensitive cooled interlined charge-coupled device camera (CoolSNAP HQ; Roper Scientific). Z positioning was accomplished by a piezoelectric motor (Linear Variable Differential Transformers LVDT; Physik Instrument), and a z series of images was taken (an image every 0.2 µm). Images were acquired with MetaMorph software (Molecular Devices).

Image processing
----------------

In [Figs. 3 A](#fig3){ref-type="fig"} and [5 C](#fig5){ref-type="fig"}, deconvolution was performed automatically using an iterative and measured point spread function--based algorithm method (Gold--Meinel) on batches of image stacks, as a service proposed by the Bioimaging Cell and Tissue Core Facility of the Institut Curie, as described in [@bib60]. Image panels were assembled with Photoshop; no digital manipulation was applied except for adjustment of brightness and contrast in [Figs. 3 (A and B)](#fig3){ref-type="fig"}, [4 C](#fig4){ref-type="fig"}, [5](#fig5){ref-type="fig"}, [6 (F and H)](#fig6){ref-type="fig"}, and [8 (E and F)](#fig8){ref-type="fig"} using ImageJ software.

Phospholipid labeling and analysis
----------------------------------

2 × 10^6^ Rab27a-silenced or control cells were pulsed with 25 µCi/ml of \[^32^P\]orthophosphate during 45 min either in TBS buffer or in RPMI 1640 media. Cells were washed tree times with cold TBS, and phosphoinositide phospholipids were extracted by a single-step acidic extraction ([@bib38]). In brief, 1 ml cell suspension was mixed with 3.75 ml chloroform/methanol/HCl (12 N; 40:80:1 vol/vol/vol). After mixing, 1.25 ml chloroform was added for 5--10 s followed by 1.25 ml of water with mixing for 5--10 s. The biphasic mixture was centrifuged at 1,000 rpm for 10 min, and the chloroform layer was transferred to another tube and dried ([@bib67]).

For TLC separation of phosphoinositide phospholipids, Silica Gel 60 TLC plates (Merck) were treated with a solution of 1% potassium oxalate in methanol/water (2:3) and warmed to 110°C for 30 min before use. TLC plates were developed by using a 1D, two-solvent system consisting of mixtures of chloroform/methanol/acetic acid/water, 25:15:8:2 vol/vol/vol/vol for the first run and 25:15:16:2 vol/vol/vol/vol for the second. After TLC plates were dried, they were exposed to the autoradiography film, incubated during 24--72 h at −70°C, and developed. In parallel, polyphosphoinositide standards obtained from Echelon were run under the same conditions and stained by iodine spraying for visualization. The Rf (relative migration factor) for each standard was calculated and used for the identification of the radioactive phospholipid samples developed by autoradiography according to previous studies ([@bib9]).

Statistical analyses
--------------------

Data were analyzed using Prism (GraphPad Software). Normality of the data was tested using the Kolmogorov--Smirnov test. Based on the normality test, either one-way analysis of variance followed by Tukey's after test or Kruskal--Wallis followed by Dunn's after test were used for multiple comparison analyses. Values are given as means ± SD. For the colocalization analysis, Manders overlap coefficient was calculated as previously described ([@bib39]). Manders colocalization maps were obtained by imaging the contribution *R~i~* of each pixel *i* of the images to the Manders overlap coefficient, calculated following$$R_{i} = \frac{S1i \times S2i}{\sqrt{{\sum\limits_{k}\left( S1k \right)^{2}} \times {\sum\limits_{k}\left( S2k \right)^{2}}}},$$where S1*i* represents the signal intensity of pixels in channel 1, and S2*i* represents the signal intensity of pixels in channel 2. This analysis was performed through a Matlab-written previously described algorithm ([@bib68]).

Online supplemental material
----------------------------

Fig. S1 shows rescue experiments for Rab27a functionality. Fig. S2 shows that Rab27a silencing alters neither HIV-1 entry nor tetherin expression. Fig. S3 shows a defect in CD63 translocation to the cell surface in Rab27a-silenced cells in which granule secretion was induced by PMA-ionomycin stimulation. Fig. S4 shows CD63 and CD81 distribution in Jurkat cells. Fig. S5 shows the biochemical association between PI4KIIα and CD63 in control, Rab27a-silenced cells, and Slp2a-silenced cells. Table S1 shows qPCR analysis of the expression of Rab27 effector proteins in Jurkat cells. Video 1 shows localization and dynamics of mCherry-CD63 and GFP-PI4KIIα in control Jurkat cells. Video 2 show localization and dynamics of mCherry-CD63 and GFP-PI4KIIα in Rab27a-silenced Jurkat cells. Video 3 shows localization and dynamics of mCherry-CD63 and GFP-PI4KIIα in Slp2a-silenced Jurkat cells. Online supplemental material is available at <http://www.jcb.org/cgi/content/full/jcb.201409082/DC1>.
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